Table 2 Summary of multivariable assessment for progression free survival.

Measure	Hazard ratio (95% CI)	p-value
Age at autoHCT (continuous)	1.01 (1.00–1.02)	<0.001
Gender
Male	Ref
Female	0.87 (0.77–0.99)	0.038
Year of autoHCT
<2010	Ref
≥2010	0.87 (0.75–1.02)	0.09
Light chain type
Kappa	Ref
Lambda	1.24 (1.09–1.41)	0.001
Biclonal	0.58 (0.27–1.23)	0.16
Unknown	0.43 (0.14–1.37)	0.15
Cytogenetic risk
Standard	Ref
High	2.02 (1.65–2.47)	<0.001
Unknown	0.99 (0.79–1.24)	0.90
Bone marrow plasma cell burden
<50%	Ref
≥50%	1.15 (1.00–1.31)	0.053
Unknown	1.16 (0.89–1.51)	0.26
R-ISS
I	Ref
II	1.06 (0.87–1.28)	0.56
III	1.40 (0.97–2.03)	0.07
Unknown	1.44 (1.19–1.74)	<0.001
LDH
Normal	Ref
>ULN	1.16 (0.91–1.48)	0.22
Unknown	0.98 (0.84–1.14)	0.80
Creatinine
≤2	Ref
>2	0.83 (0.65–1.06)	0.13
Unknown	0.78 (0.58–1.04)	0.09
\({{\boldsymbol{\beta }}}_{{\bf{2}}}\) microglobulin (continuous)	1.01 (1.00–1.03)	0.08
Induction regimen^a
VRD	Ref
Non-VRD	1.09 (0.91–1.30)	0.36
Prior MRD/response
Other^b	Ref
Not detected/≥VGPR	0.64 (0.48–0.86)	0.003
Maintenance^c
Yes vs. No	0.79 (0.68–0.92)	0.002
Hematologic best response^c
CR vs. non-CR	0.62 (0.54–0.71)	<0.001

autoHCT autologous hematopoietic stem cell transplant, CI confidence interval, CR complete response, LDH lactate dehydrogenase, MRD minimal residual disease, Ref reference level, R-ISS Revised International Staging System, ULN upper limit normal, VGPR very good partial response, VRD bortezomib, lenalidomide, dexamethasone.
^aInduction regimens were reclassified into two categories: VRD vs. non-VRD.
^bDefined as: [patients with a response of <VGPR with any MRD status prior to transplant] OR [patients with a response of ≥VGPR and MRD positive status prior to transplant].
^cIncluded as a time-dependent variable in the model.

Quick links

Search